Halos opens early-stage drug development to investors — letting you back individual drug candidates, the platform itself, or a managed portfolio. High-risk, high-conviction, and built on transparency.
Investing involves substantial risk, including loss of your entire investment. Drug candidates may never reach approval.
Most ways to invest in drug development bundle hundreds of programs together. Halos does the opposite: each drug candidate is its own asset, with its own science, its own stage of development, and its own risk profile — laid out so you can decide for yourself.
Profiles shown as “Coming soon.” Reservation of interest is not an offer to sell or a solicitation to buy securities. No money is being accepted at this time.
See the full catalogDifferent goals, different eligibility, different risk. Here’s how each works and who it’s for. All investments are high-risk and illiquid.
Invest in a single drug candidate you believe in. As the program develops, follow its progress on its profile.
Invest in Halos itself and the marketplace we’re building, alongside the team operating it.
Invest in a managed fund holding a diversified basket of drug assets. Quarterly NAV. Hands-free.
Every asset on Halos follows a clear lifecycle. We show you where each one stands and what has to happen next.
Most drug candidates that enter clinical development are never approved. Investments are illiquid; be prepared to hold for years or lose your entire investment.
Browse the catalogFounded 2024 · a small team of operators, scientists, and finance people.
Halos was founded to close the gap between promising early-stage science and the investors who want to support it — without pretending the risks away. We believe investors deserve to understand exactly what they’re backing, and that the science deserves to be explained, not oversold.
Halos works with established legal, financial, and compliance partners. Logos and roles below are representative placeholders.
Create an account to explore assets in depth, reserve interest in upcoming drug offerings, and — if you’re an accredited investor — invest in the platform or the fund today.